The persistence, biodistribution, and risk of integration into the host genome of any new therapeutic DNA vaccine must be established in preclinical studies. We previously developed the DNA vaccine pcDNA-CCOL2A1 ...
from Most Recent Articles: Journal of Nanobiotechnology https://ift.tt/2UI9h1F
via IFTTT
No comments:
Post a Comment